Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine for platelet engraftment after autologous HSCT
IRCT20211123053165N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in multiple myeloma (MM) and lymphoma comparing N-acetylcysteine plus routine treatment with Placebo plus routine treatment (2 arms). Primary endpoints: Days without need for platelet infusion and Platelet count monitoring. Started Dec 2021; status: completed.
02
Drugs
acetylcysteine
03
Conditions
multiple myeloma (MM)lymphoma
Beyond the preview
Go deeper on IRCT20211123053165N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211123053165N1.